|
Patent landscape, scope, and claims: |
United States Patent 11,999,744: Scope, Claim Architecture, and US Patent Landscape for Crystalline Form A in Systemic Mastocytosis
US Patent 11,999,744 claims a method of treating systemic mastocytosis by administering a specific drug solid state: crystalline Form A of “Compound (I)”, where Form A is defined by X-ray powder diffraction (XRPD) peak sets and DSC thermal behavior, with additional claim strata covering mastocytosis subtype, KIT exon 17 (including D816V), and a dosing example (200 mg once daily). The asserted novelty and enforceable core sit in the form identity (Form A) tied to objective characterization plus the use (systemic mastocytosis).
What is claimed? (Independent claim and core enforceable subject matter)
H1 Independent claim 1: What must be done and what must be the drug solid form
Claim 1 is a combination of:
- Medical use: treating systemic mastocytosis.
- Act: administering to a patient in need thereof a therapeutically effective amount of crystalline Form A of Compound (I).
- Identity of Form A: the crystalline Form A is characterized by an XRPD diffractogram that comprises at least three peaks at 2θ angles selected from:
- 11.5 ± 0.2
- 15.4 ± 0.2
- 16.7 ± 0.2
- 20.0 ± 0.2
- 21.6 ± 0.2
Enforcement practical meaning: infringement turns on (1) the presence of the clinical indication within the claim (systemic mastocytosis), and (2) the administered material meeting the XRPD peak-set constraint for Form A.
H2 Claim dependency map: how the scope narrows
Claims 2-6 define the XRPD peak sufficiency and a DSC event, Claims 7-14 narrow the patient population and disease subtype and KIT genotype, and Claim 9 adds a specific dosing regimen.
How broad is the XRPD-defined “crystalline Form A” scope?
H2 Claim 1 vs claim 2-5: peak-count and peak-set breadth
Claims differ by requiring more XRPD peaks within a fixed menu of candidate peak positions.
XRPD peak sets by claim
| Claim |
XRPD requirement |
2θ candidates included |
Minimum peaks required |
| 1 |
At least three peaks |
11.5, 15.4, 16.7, 20.0, 21.6 (each ±0.2) |
3 |
| 2 |
At least seven peaks |
11.5, 15.4, 16.7, 18.1, 20.0, 21.6, 23.1, 23.9, 25.9, 30.7 (each ±0.2) |
7 |
| 3 |
At least eight peaks |
same 10 candidates |
8 |
| 4 |
Peaks at each listed angle |
same 10 candidates |
10 (explicit “peaks at”) |
| 5 |
Peaks at a subset |
11.5, 15.4, 16.7, 20.0, 21.6 (each ±0.2) |
5 |
Scope implication:
- Claim 1 is the broadest XRPD identity gate: any Form A material that yields at least three of five candidate peaks (within ±0.2° 2θ) can satisfy the characterization.
- Claims 2-4 progressively tighten by requiring 7/10, 8/10, or all 10 candidate peaks.
- Claim 5 selects a five-peak subset (all five must appear) but still uses a smaller menu than claims 2-4.
H2 Which XRPD angles are the “workhorse” peaks?
Across the claim set, the peaks that recur in the narrowest subsets include:
- 11.5 ± 0.2
- 15.4 ± 0.2
- 16.7 ± 0.2
- 20.0 ± 0.2
- 21.6 ± 0.2
These also appear in Claim 1’s entire candidate set, making them the minimal shared signature across the family.
Thermal characterization: DSC constraint and how it limits design-arounds
H2 Claim 6: DSC endpoint as an additional identity hook
Claim 6 adds a DSC requirement to Form A characterization:
- Endothermic event with a signal at 194°C to 195°C, or an onset temperature of 193°C.
Scope implication:
- If a competitor or formulation uses an alternative solid state that meets XRPD peak count but shifts thermal events outside the claimed window/onset, it can potentially avoid a claim that includes DSC limitations.
- Practically, Claim 6 is dependent on claim 1, so the DSC requirement would only matter if the asserted claim includes it. Claim 1 itself does not require DSC.
Disease scope: systemic mastocytosis subtype coverage
H2 Claims 7-11: which systemic mastocytosis categories are explicitly covered
Claims specify subtypes:
- Claim 7: Smoldering systemic mastocytosis (SSM)
- Claim 8: Advanced systemic mastocytosis (AdvSM)
- Claim 10: Aggressive systemic mastocytosis (ASM), SM-AHN, and MCL
- Claim 11: Indolent systemic mastocytosis (ISM)
Scope implication:
- The patent covers the full span from indolent through aggressive/malignant phenotypes as explicitly named.
- This breadth reduces the ability to steer around by restricting clinical target to an unclaimed systemic mastocytosis category (at least among those enumerated).
H2 Claim 8 + Claim 9: dosing constraint tied to AdvSM
- Claim 8: systemic mastocytosis is AdvSM
- Claim 9: 200 mg of crystalline Form A of Compound (I) administered once daily
Scope implication:
- Claim 9 is narrower than claims 7-8 in its dosing specificity.
- A regimen that treats AdvSM but uses a different dose frequency/dose could avoid Claim 9 while still potentially implicating Claim 8 or Claim 1-4 (depending on asserted claim).
Biomarker-genotype scope: KIT exon 17 and D816V
H2 Claims 12-14: patient selection by KIT genotype
- Claim 12: patient has a mutation in Exon 17 in KIT
- Claim 13: the mutation is D816 in KIT, Exon 17
- Claim 14: D816V
Scope implication:
- The claims explicitly anchor to the most common oncogenic KIT driver in systemic mastocytosis contexts.
- If a competitor positions a therapy for patients without KIT exon 17 mutations, it can potentially avoid the dependent KIT-specific claims (12-14) but may still fall under Claim 1 if systemic mastocytosis treatment is otherwise in-scope and the crystalline Form A definition is met.
Where the enforceable core sits (what actually needs to be proven)
H2 Proof elements likely to matter in litigation
For Claim 1, a patentee typically needs to show:
- A product/form meets “crystalline Form A” as defined by XRPD with at least three peaks from the specified five candidate positions (each within ±0.2° 2θ).
- A therapeutically effective amount is administered to a patient with systemic mastocytosis.
- The administered formulation corresponds to crystalline Form A (not just “contains” the drug).
For dependent claims:
- Claims 2-5 require higher or specific peak presence counts.
- Claim 6 adds DSC window/onset criteria.
- Claims 7-11 add clinical subtype constraints.
- Claims 12-14 add genotype constraints.
- Claim 9 adds a dose regimen.
US patent landscape: likely contours around Form A, method of use, and solid-state barriers
H2 Patent landscape structure for this kind of claim set
Without reproducing unprovided patent family data, the landscape relevant to US 11,999,744 typically splits into three buckets:
-
Compound / active ingredient patents (composition and/or early method claims)
- These may claim Compound (I) itself, salts, polymorphs, and broader therapeutic uses.
- If they exist, they define the floor: even if Form A is avoided, the active ingredient can still be protected.
-
Solid-state / polymorph / Form identity patents
- Your claim set indicates the enforceable differentiation is crystalline Form A with objective XRPD/DSC signatures.
- Landscape risk for entrants often comes from multiple solid-form patents that each define a different polymorph, hydrate, or amorphous-to-crystalline transition product.
-
Method-of-use patents in mastocytosis and KIT-driven cohorts
- Claims 7-14 show a second enforceable axis: systemic mastocytosis indication plus KIT exon 17/D816V selection.
- Many landscapes contain both broad “systemic mastocytosis” claims and narrower subtype/genotype claims.
H2 How competitors commonly design around this claim architecture
Given the rigid objective form characterization:
- XRPD-based avoidance: produce an alternative polymorph or a Form A variant that does not satisfy the peak count/position criteria within ±0.2°.
- Thermal avoidance: satisfy XRPD but shift DSC endotherm/onset outside 194-195°C signal or 193°C onset, targeting Claim 6 specifically.
- Indication avoidance: target non-systemic-mastocytosis indications or restrict evidence to categories not covered, though your claim set enumerates multiple systemic subtypes.
- Dose regimen avoidance: adjust regimen away from 200 mg once daily to avoid Claim 9.
- Genotype cohort avoidance: enroll only mutation-negative patients to avoid Claims 12-14, while leaving Claim 1 as the remaining risk.
Scope summary (what you can and cannot read into the claims)
H2 Claim coverage matrix
| Dimension |
Broad coverage |
Narrowing constraints |
| Solid form |
Crystalline Form A defined by XRPD |
Claims 2-5 require higher peak counts or specific sets; Claim 6 adds DSC window |
| Indication |
Systemic mastocytosis generally (Claim 1) |
Claims 7-11 limit to SSM/AdvSM/ASM/SM-AHN/MCL/ISM |
| Genotype |
Not required in Claim 1 |
Claims 12-14 require KIT exon 17 mutation, specifically D816/D816V |
| Regimen |
“Therapeutically effective amount” |
Claim 9 limits to 200 mg once daily (AdvSM context) |
Key Takeaways
- US 11,999,744’s enforceable center is “crystalline Form A” defined by XRPD. Claim 1 only requires at least 3 peaks from five candidate angles (±0.2° 2θ), giving the widest solid-state capture within the family.
- Claims 2-5 tighten Form A by requiring 7+, 8+, 10/10, or exact five-peak presence patterns using the stated candidate angles.
- Claim 6 adds DSC identity (endotherm 194-195°C or onset 193°C), creating a second characterization gate that can be targeted separately from XRPD-based defenses.
- Disease coverage is broad across systemic mastocytosis subtypes: ISM, SSM, AdvSM, ASM, SM-AHN, and MCL.
- Patient selection is covered via KIT exon 17 mutation and D816V (Claims 12-14), and AdvSM dose is constrained to 200 mg once daily (Claim 9).
FAQs
1) What is the minimum XRPD requirement in Claim 1?
At least three peaks at 2θ angles selected from 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 20.0 ± 0.2, and 21.6 ± 0.2.
2) Does Claim 1 require DSC confirmation?
No. DSC is required only in Claim 6.
3) Which claims explicitly cover KIT D816V?
Claims 12-14, with Claim 14 requiring D816V in KIT Exon 17.
4) Is the patent limited to AdvSM dosing of 200 mg once daily?
That specific regimen is in Claim 9, which depends on AdvSM (Claim 8). Other claims do not impose that exact regimen.
5) Which systemic mastocytosis subtypes are named?
ISM (Claim 11), SSM (Claim 7), AdvSM (Claim 8), ASM (Claim 10), SM-AHN (Claim 10), and MCL (Claim 10).
References
[1] US Patent 11,999,744. Claims 1-14 (method of treating systemic mastocytosis using crystalline Form A characterized by XRPD and DSC).
More… ↓
⤷ Start Trial
|
